Related Experiment Video

Updated: Apr 15, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.4K

Targeted therapy in soft tissue sarcoma-a novel direction in therapeutics

Chun Jek Tan1, Jia-Lin Yang2, Philip Crowe1

  • 1Sarcoma Research Group, Adult Cancer Program, Lowy Cancer Research Centre, Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Surgery, Prince of Wales Hospital, Randwick, NSW 2031, Australia.

Chinese Clinical Oncology
|April 6, 2015
PubMed

Insights

Chemotherapy resistance is a major challenge in soft tissue sarcoma (STS) treatment. This review explores combining targeted therapies to overcome resistance caused by alternative signaling pathways.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Chemotherapy resistance is a significant challenge in treating soft tissue sarcomas (STS).
  • Targeted therapies have emerged as novel treatment options for STS.
  • Monotherapy with targeted agents has yielded suboptimal results due to pathway activation.

Purpose of the Study:

  • To review the potential of combining targeted agents to overcome chemotherapy resistance in STS.
  • To explore strategies for improving treatment efficacy in soft tissue sarcomas.

Main Methods:

  • Literature review of targeted therapies in soft tissue sarcoma treatment.
  • Analysis of signaling pathways involved in drug resistance.
  • Examination of combination therapy approaches.

Main Results:

  • Targeted agents show promise but often face resistance.
  • Activation of alternative signaling pathways contributes to monotherapy failure.
  • Combination strategies may offer a way to enhance treatment effectiveness.

Conclusions:

  • Tactical combinations of targeted agents hold potential for overcoming resistance in STS.
  • Further research into combination therapies is warranted for improved STS outcomes.
Keywords:
Combination therapyresistancesarcomasignaling pathwaytargeted therapy

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.5K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
141
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K